U.S. flag

An official website of the United States government

GTR Home > Tests > Pharmacogenomic Testing

Indication

This is a clinical test intended for Help: Diagnosis, Drug Response, Risk Assessment

Clinical summary

Help

Check Clinical features section (below), Conditions for which test is offered (above), and links on the right for additional information about this condition.

Conditions tested

Target population

Help

Individuals who have poor reactions or no symptomatic relief from multiple drugs, using multiple drugs, may start a new drug, want to switch to a different drug. Indications may include depression, anxiety, epilepsy, ADHD, and more.

Citations

  • Pharmacogenetic testing for the guidance of psychiatric treatment: a multicenter retrospective analysis. - PubMed ID: 27098095
  • Clinical Impact of Pharmacogenetic-Guided Treatment for Patients Exhibiting Neuropsychiatric Disorders: A Randomized Controlled Trial. - PubMed ID: 28314093
  • Efficacy of prospective pharmacogenetic testing in the treatment of major depressive disorder: results of a randomized, double-blind clinical trial. - PubMed ID: 28705252
  • Improved efficacy with targeted pharmacogenetic-guided treatment of patients with depression and anxiety: A randomized clinical trial demonstrating clinical utility. - PubMed ID: 28992526
  • Clinical utility of pharmacogenetic testing in children and adolescents with severe mental disorders. - PubMed ID: 29626260
  • <i>CYP2D6</i> genotype can help to predict effectiveness and safety during opioid treatment for chronic low back pain: results from a retrospective study in an Italian cohort. - PubMed ID: 30425549
  • CYP2D6-guided opioid therapy improves pain control in CYP2D6 intermediate and poor metabolizers: a pragmatic clinical trial. - PubMed ID: 30670877
  • Impact of pharmacogenomics on clinical outcomes in major depressive disorder in the GUIDED trial: A large, patient- and rater-blinded, randomized, controlled study. - PubMed ID: 30677646
  • - PubMed ID: 30859976

Clinical validity

Help

Pharmacogenetics is the study of genetic variations that influence medication response. The field is a combination of pharmacology and genomics, enabling medical professionals to predict whether a patient may have a normal response, a poor response, or a higher risk of side effects for many medications. The three main authorities in this field are Clinical Pharmacogenetics Implementation Consortium (CPIC), The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group (DPWG), and the Food and Drug Administration (FDA). The recommendations in these guidelines are conveniently displayed on the PharmGKB website entitled “Dosing Guidelines” with a listing of the original studies (see https://www.pharmgkb.org/guidelines).

Citations

Not provided

Clinical utility

Help

Not provided

IMPORTANT NOTE: NIH does not independently verify information submitted to the GTR; it relies on submitters to provide information that is accurate and not misleading. NIH makes no endorsements of tests or laboratories listed in the GTR. GTR is not a substitute for medical advice. Patients and consumers with specific questions about a genetic test should contact a health care provider or a genetics professional.